SAB Biotherapeutics develops human polyclonal antibody therapeutics produced using genetically engineered transchromosomic cattle. Its lead candidate is a fully human multi-specific anti-thymocyte globulin in clinical trials for Type 1 diabetes, intended to act as a disease-modifying therapy that delays progression by preserving beta cell function. The platform enables production of high-potency human immunoglobulins for immune-mediated diseases without human donors or convalescent plasma.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -10.1 | — |
| Q3 2025 | 0 | — | 45.5 | — |
| Q4 2025 | 0 | — | -16.9 | — |
| Q1 2026 | 0 | — | -18.9 | — |
| Q2 2026 | 0 | — | -22.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Global Water Resources, Inc. (GWRS), ProQR Therapeutics N.V. (PRQR), Crown Reserve Acquisition Corp. I (CRAC), Alliance Entertainment Holding Corporation (AENT), BitFuFu Inc. (FUFU), UTime Limited (FXHO)